HIV genital shedding and safety of Carraguard use by HIV-infected women: A crossover trial in Thailand

AIDS

Volumn 24, Issue 5, 2010, Pages 717-722

  McLean, Catherine A ^a   Van De Wijgert, Janneke Hhm ^b,c   Jones, Heidi E ^b,d   Karon, John M ^e   McNicoll, Janet M ^a,f   Whitehead, Sara J ^a,f   Braunstein, Sarah ^b,d   Achalapong, Jullapong ^g   Chaikummao, Supaporn ^f   Tappero, Jordan W ^a,f   Markowitz, Lauri E ^a   Kilmarx, Peter H ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b POPULATION COUNCIL   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d NewYork Presbyterian Hospital   (United States)

^e Emergint Corporation   (United States)

^f MINISTRY OF PUBLIC HEALTH   (Thailand)

^g Chiang Rai Prachanukhro Hospital   (Thailand)

Author keywords

Clinical trials; HIV; Prevention of sexual transmission; Thailand; Vaginal microbicides; Virus shedding

Indexed keywords

ANTIRETROVIRUS AGENT; CARRAGEENAN; HEMOGLOBIN; METHYLCELLULOSE; PLACEBO; VIRUS RNA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG SAFETY; FEMALE; FEMALE GENITAL SYSTEM; GEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LEUKOCYTE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; THAILAND; TREATMENT DURATION; TREATMENT OUTCOME; UTERINE CERVIX CYTOLOGY; VAGINA; VAGINA FLORA; VAGINA SMEAR; VIRUS LOAD; VIRUS SHEDDING;

ADMINISTRATION, INTRAVAGINAL; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; CARRAGEENAN; CD4 LYMPHOCYTE COUNT; CROSS-OVER STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; SEXUAL BEHAVIOR; THAILAND; TREATMENT OUTCOME; VAGINAL CREAMS, FOAMS, AND JELLIES; VIRAL LOAD; VIRUS SHEDDING;

EID: 77949390639     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328333bf89     Document Type: Article

References (15)

1. Harrisons P, Rosenberg S, Bowcut J. Topical microbicides for disease prevention: status and challenges. Clin Infect Dis 2003; 36:1290-1294.
2. Maguire RA, Bergman N, Phillips DM. Comparison of micro-bicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex Transm Dis 2001; 28:259-265.
3. Pearce-Pratt R, Phillips DM. Sulphated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol Reprod 1996; 54:173-182.
4. Zacharapoulos V, Phillips D. Vaginal formulations of carragee-nan protect mice from herpes simplex virus infection. Clin Diag Lab Immunol 1997; 4:465-468.
5. Kilmarx PH, van de Wijgert J, Chaikummao S, Jones H, Limpa-karnjanarat K, Friedland B, et al. Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a phase II clinical trial. J Acquir Immune Defic Syndr 2006; 43:327-334.
6. van de Wijgert J, Braunstein S, Morar N, Jones H, Madurai L, Evans Strickfaden E, et al. Carraguard vaginal gel safety and effect on HIV RNA shedding among HIV-positive women and men in South Africa. J Acquir Immune Defic Syndr 2007; 46:538-546.
7. Kilmarx PH, Blanchard K, Chaikummao S, Friedland BA, Srivir-ojana N, Connolly C, et al. A randomized, placebo-controlled trial to assess the safety and acceptability of use of Carraguard vaginal gel by heterosexual couples in Thailand. Sex Transm Dis 2008; 35:226-232.
8. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1977-1987.
9. Fernández-Romero JA, Thorn M, Turville SG, Titchen K, Sudol K, Li J, et al. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis 2007; 34:9-14.
10. Mauck C, Rosenberg Z, Van Damme L, International Working Group on Microbicides. Recommendations for the clinical development of topical microbicides: an update. AIDS 2001; 15:857-868.
11. Senn S. Crossover trials in clinical research. 2nd ed. West Sussex, England: John Wiley & Sons; 2002.
12. Coetzee N, Blanchard K, Ellertson C, Hoosen A, Friedland B. Acceptability and feasibility of Micralax applicators and of methylcellulose placebo for large-scale clinical trials of vaginal microbicides. AIDS 2001; 15:1837-1842.
13. CONRAD and World Health Organization. Manual for the standardization of colposcopy for the evaluation of vaginal products. Update 2004. Geneva, Switzerland: WHO 2004.
14. Bollen L, Kilmarx PH. Photo atlas for microbicide evaluation. Bangkok, Thailand: Thailand MOPH-U.S. CDC Collaboration; 2002.
15. Leelawiwat W, McLean CM, Tasaneeyapan T, Sinthwattanawi-bool C, Evans-Strickfaden T, Kilmarx PH, et al. In vitro effect of Carraguard, a candidate microbicide, on standard HIV RNA Roche Amplicor PCR testing and on as modified assay (NasMo) in simulated HIV cervicovagina lavage samples. In: 13th IUSTI Asia Pacific Conference; 6-9 July 2004; Chiang Mai, Thailand.